

23394

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 45/06</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/07447</b> <b>(43) International Publication Date:</b> 26 February 1998 (26.02.98)
<b>(21) International Application Number:</b> PCT/US97/14680 <b>(22) International Filing Date:</b> 21 August 1997 (21.08.97)  <b>(30) Priority Data:</b> 60/024,508                      23 August 1996 (23.08.96)                      US  <b>(71) Applicant (for all designated States except US):</b> ALGOS PHARMACEUTICAL CORPORATION [US/US]; Colling- wood Plaza, 4900 Route 33, Neptune, NJ 07753 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> CARUSO, Frank, S. [US/US]; 2 Bowling Green, Colts Neck, NJ 07722 (US). MINN, Fredrick, L. [US/US]; 601 Midway Lane, Blue Bell, PA 19422 (US). LYLE, John, W. [US/US]; 28 Inlet Terrace, Belmar, NJ 07719 (US).  <b>(74) Agents:</b> DILWORTH, Peter, G. et al.; Dilworth & Barrese, 333 Earle Ovington Boulevard, Uniondale, NY 11553 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> ANTICONVULSANT CONTAINING COMPOSITION FOR TREATING NEUROPATHIC PAIN		
<b>(57) Abstract</b>  Composition for alleviating neuropathic pain which a neuropathic pain-alleviating amount of an anticonvulsant is combined with an anticonvulsant-potentiating amount of a nontoxic antagonist, or blocker, for the N-methyl-D-aspartate (NMDA) receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China			PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## 5      ANTICONVULSANT CONTAINING COMPOSITION FOR TREATING NEUROPATHIC PAIN

BACKGROUND OF THE INVENTION

10      This invention relates to a composition and method for alleviating neuropathic pain. More particularly, this invention is directed to a composition and method for alleviating neuropathic pain in which a neuropathic pain-alleviating amount of an anticonvulsant is combined with an anticonvulsant-potentiating amount of a nontoxic antagonist, or blocker, for the N-methyl-D-aspartate (NMDA) receptor or  
15      nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation.

20      Neuropathic pain is pain that is due to functional abnormalities of the nervous system. Fields, "Pain", McGraw-Hill, Inc. (1987), pp. 133 et seq. There are a variety of possible mechanisms by which nerve dysfunction can cause neuropathic pain: hyperactivity in primary afferent or central nervous system (CNS) nociceptive neurons, loss of central inhibitory connections, and increased activity in sympathetic efferents. Neuropathic  
25      pain typically occurs following injury to elements of the nervous system involved in nociception, such as peripheral nerve injury, in which the lesions deafferent the nociceptive pathway, the resultant pain sometimes being referred to deafferentation pain. Neuropathic pain is much  
30      more likely to occur with peripheral than with central nervous system damage. Examples of causes of painful nerve injury are: accidental trauma, tumors, cervical or lumbar spine disease, and surgical procedures. These injuries

usually involve one or two peripheral nerves or nerve roots, and the pain is felt in the body region normally innervated by the damaged nerves. Additionally, there are also toxic, metabolic, and hereditary causes of painful polyneuropathies, e.g., alcohol abuse, diabetes mellitus. These tend to be symmetrical and are most severe on the distal limbs.

#### SUMMARY OF THE INVENTION

In accordance with the present invention, a drug composition is provided which comprises a neuropathic pain-alleviating amount of at least one anticonvulsant in combination with an anticonvulsant-potentiating amount of at least one nontoxic antagonist for the NMDA receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation.

Further in accordance with the present invention, a method of alleviating neuropathic pain is provided which comprises administering to a mammal exhibiting neuropathic pain (a) a neuropathic pain-alleviating amount of at least one anticonvulsant and (b) an anticonvulsant-potentiating amount of at least one nontoxic antagonist for the NMDA receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation with (a) being administered prior to, with or following the administration of (b).

The expression "N-methyl-D-aspartate receptor" shall be understood to include all of the binding site subcategories associated with the NMDA receptor, e.g., the glycine-binding site, the phenylcyclidine (PCP)-binding site, etc., as well as the NMDA channel. Thus, the invention herein contemplates the use of nontoxic substances

that block an NMDA receptor binding site, e.g., dextrorphan, or the NMDA channel, e.g., a source of magnesium such as magnesium sulfate.

The term "nontoxic" as used herein shall be understood in a relative sense and is intended to designate any substance that has been approved by the United States Food and Drug Administration ("FDA") for administration to humans or, in keeping with established regulatory criteria and practice, is susceptible to approval by the FDA for administration to humans. The term "nontoxic" is also used herein to distinguish the NMDA receptor antagonists, or blockers, that are useful in the practice of the present invention from NMDA receptor antagonists such as MK 801 (the compound 5-methyl-10,11-dihydro-SH-dibenze[a,d] cyclohepten-5,10-imine), CPP (the compound 3-[2-carboxypiperazin-4-yl] propyl-1-phosphonic acid) and PCP (the compound 1-(1-phenylcyclohexyl)piperidine) whose toxicities effectively preclude their therapeutic use.

The expression "neuropathic pain-alleviating" shall be understood herein to include the expressions "neuropathic pain-suppressing" and "neuropathic pain-inhibiting" as the invention is applicable to the alleviation of existing neuropathic pain as well as the suppression or inhibition of neuropathic pain which would otherwise ensue from an imminent neuropathic pain-causing event.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

Any of the pain-alleviating anticonvulsants can be used herein. For extensive listings of anticonvulsants, see, e.g., Goodman and Gilman's "The Pharmaceutical Basis Of

Therapeutics", 8th ed., McGraw-Hill, Inc. (1990), pp. 436-462, and "Remington's Pharmaceutical Sciences", 17th ed., Mack Publishing Company (1985), pp. 1075-1083. Specific neuropathic pain-alleviating anticonvulsants that can be  
5 used herein include lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide,  
10 progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan.

Among the nontoxic substances that block the NMDA  
15 receptor and as such are useful for potentiating the neuropathic pain-alleviating activity of the anticonvulsant in accordance with this invention are dextromethorphan ((+)-3-hydroxy-N-methylmorphinan), its metabolite dextrorphan ((+)-3-hydroxy-N-methylmorphinan), amantadine (1-amino  
20 adamantine), memantine (3,5 dimethylaminoadamantone), their mixtures and their pharmaceutically acceptable salts. Other useful nontoxic substances that block the NMDA receptor include pyrroloquinoline quinone and cis-4-(phosphono-methyl)-2-piperidinecarboxylic acid.

25 In addition to, or in place of, a blocker for the NMDA receptor, at least one nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation can also be used. Activation of the NMDA receptor, a subtype of excitatory amino acid receptors, induces a number  
30 of changes in the functional activity of nerve cells and, in particular, their capacity for excitability or inhibition in

the presence of an addictive substance via an increase in intracellular  $\text{Ca}^{++}$  concentration. The major consequences of NMDA receptor activation include the following sequences, or cascades, of events occurring within nerve cells:

5           a) translocation and activation of protein kinases such as protein kinase C  $\rightarrow$  phosphorylation of substrate proteins such as cytosolic enzymes, channel proteins, receptor proteins, etc.  $\rightarrow$  changes in functional activity;

10           b) initiation of early gene (*c-fos*, *c-jun*, *zif-268*, etc.) expression by either increased intracellular  $\text{Ca}^{++}$  or  $\text{Ca}^{++}$ -activated protein kinases  $\rightarrow$  expression of functional genes responsible for production of cellular enzymes (such as protein kinases), receptor proteins (such as the NMDA  
15 receptor), ion channel proteins (such as  $\text{K}^{+}$ ,  $\text{Na}^{+}$ ,  $\text{Ca}^{++}$  channels), neuropeptides (such as dynorphin), etc.  $\rightarrow$  changes in functional activity;

          c)  $\text{Ca}^{++}$ /calmodulin (or other  $\text{Ca}^{++}$  binding proteins) induced activation of enzymes and other cellular  
20 components  $\rightarrow$  activation of  $\text{Ca}^{++}$ /calmodulin-protein kinase systems such as  $\text{Ca}^{++}$ /calmodulin kinase II  $\rightarrow$  autophosphorylation of enzymes (e.g.,  $\text{Ca}^{++}$ /calmodulin kinase II) or other functional proteins  $\rightarrow$  changes in functional activity;

25           d)  $\text{Ca}^{++}$ /calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase  $\rightarrow$  production of nitric oxide  
 $\rightarrow$  i) production of cyclic guanosine monophosphate via activation of guanosine cyclase resulting in activation of  
30 protein kinases and early gene expression; ii) direct protein modification such as enzymes, receptor and/or

channel proteins; iii) lipid membrane modification and/or nucleic acid modification via scavenge of free radicals; iv) induction of neurotoxicity at higher nitric oxide levels; v) retrograde actions in adjacent neurons or glial cells such as facilitation of glutamate release/NMDA receptor activation and/or inhibition of post-synaptic NMDA receptors → changes in functional activity;

e) interactions with the cyclic adenosine monophosphate/protein kinase A system, the phospholipase C-inositol triphosphate- $\text{Ca}^{++}$ /diacylglycerol-protein kinase system, the phospholipase A2-arachidonic acid/prostanoids/leukotrienes system → changes in functional activity induced by second messenger systems other than NMDA receptor/ $\text{Ca}^{++}$ / $\text{Ca}^{++}$ -calmodulin/protein kinase systems; and,

f) interactions with other excitatory amino acid receptor subtypes including non-NMDA receptors and metabotropic receptors as well as intracellular events subsequent to the activation of these excitatory amino acid receptor subtypes → changes in functional activity induced by the non-NMDA and metabotropic receptor activation.

A substance that blocks the NMDA receptor will effectively prevent all of the foregoing major intracellular sequences of events from taking place. However, even with activation of the NMDA receptor, it is still possible to treat neuropathic pain in accordance with this invention by administering the anticonvulsant and a nontoxic substance that blocks at least one of the foregoing major intracellular sequences of events brought about by activation of the NMDA receptor. Thus, e.g., a substance that interferes with translocation and activation of protein kinase C or with calmodulin induced activation of constitutive nitric



oxide synthase as well as induction of inducible nitric oxide synthase is also useful for the practice of this invention.

Nontoxic substances that block a major  
5 intracellular consequence of NMDA receptor activation and are therefore useful in the practice of the invention include inhibitors of protein kinase C, e.g., gangliosides such as ganglioside GM<sub>1</sub> (monosialoganglioside) and ganglioside GT<sub>1b</sub> (trisialoganglioside); amphipathic long  
10 chain bases such as sphingosine, N,N,N-trimethylsphingosine, sphinganine and psychosine; quinolyloxazole-2-ones such as 4-methyl-5-(3-quinolinyl)-2-(3H)-oxazolone and phenyl-5-(2-quinolinyl)-2-3(3H)-oxazolone; 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones such as 1,4-bis-(3-  
15 propylamino-2-hydroxypropylamino)-9,10 anthracenedione and 1,4-bis-(3-benzylamino-2-hydroxypropylamino)-9,10 anthracenedione; and, mixtures and pharmaceutically acceptable salts of any of the foregoing.

Additional nontoxic substances that block a major  
20 intracellular consequence of NMDA receptor activation and as such are useful in the practice of the invention include inhibitors of calmodulin such as the phenothiazines, in particular, chlorpromazine, chlorpromazine sulfoxide, prochlorperazine dimaleate, perphenazine, trifluoperazine,  
25 fluphenazine, fluphenazine enanthate, fluphenazine decanoate, thioridazine, mesoridazine besylate, piperacetazine, acetophenazine dimaleate, carphenazine dimaleate, butaperazine dimaleate and phenothiazine sulfoxide; naphthalenesulfonamides such as N-(6-aminohexyl)-  
30 5-chloro-1-naphthalenesulfonamide, N-(6-aminohexyl)-5-chloro-2-naphthalenesulfonamide and N-(6-aminohexyl)-5-

bromo-2-naphthalenesulfonamide; 4-substituted-4H,6H-pyrrolo[1,2-a][4,1] benzoxazepines such as 1,3-dihydro-1-{1-[(4-methyl-4H,6H-pyrrolo[1,2-a][4,1] benzoxazepin-4-yl)methyl]-4-piperidinyl}-2H-benzimidazol-2-one; benzhydryls  
5 such as N-[2](diphenylmethylthioethyl)-2-(trifluoromethyl)-benzeneethanamine, N-[2-(bis(4-fluorophenyl)methylthio)-ethyl]-2-(trifluoromethyl)benzeneethanamine and N-[2-(bis(4-fluorophenyl)methylthio)ethyl]-3-(trifluoromethyl)benzeneethanamine; tricyclic antidepressant drugs such as  
10 imipramine, 2-chloroimipramine and amitriptyline; penfluridol; haloperidol; pimozide; clozapine; calmidazolin; and, mixtures and pharmaceutically acceptable salts of any of the foregoing.

Of the two groups, the NMDA-receptor antagonists  
15 are preferred and of these, dextromethorphan is especially preferred due to its wide use in over-the-counter medications where it functions as a cough suppressant.

With regard to dosage levels, the anticonvulsant must be present in a neuropathic pain-alleviating amount,  
20 e.g., at a level corresponding to the generally recommended adult human dosages for a particular anticonvulsant, and the NMDA receptor blocker or substance that blocks a major intracellular consequence of NMDA activation must be present at a level that potentiates the neuropathic pain-alleviating effectiveness of the anticonvulsant. Specific dosage levels  
25 for the anticonvulsants that can be used herein as given, inter alia, in the "Physicians' Desk Reference", 1996 Edition (Medical Economics Data Production Company, Montvale, NJ) as well as in other reference works including  
30 Goodman and Gilman's "The Pharmaceutical Basis of Therapeutics" and "Remington's Pharmaceutical Sciences" both

of which as referred to above. Given the wide variation in dosage level of the anticonvulsant which depends to a large extent on the specific anticonvulsant being administered, there can similarly be a wide variation in the dosage level of the NMDA receptor blocker or substance that blocks a major intracellular consequence of NMDA receptor activation. These amounts can be determined for a particular drug combination in accordance with this invention employing routine experimental testing. In case of the anticonvulsant phenobarbital and the NMDA receptor blocker dextromethorphan, dosages of from 50 to 300 mg/day of the former coadministered with from 30 to 120 mg/day of the latter will usually provide acceptable results.

While the neuropathic pain-alleviating anti-convulsant and anticonvulsant-potentiating nontoxic NMDA receptor blocker or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation need not be administered together, they must both be present in the patient at effective levels at the same time. While it is within the scope of the invention to separately administer the anticonvulsant and the NMDA receptor blocker or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation, as a matter of convenience, it is preferred that these drugs be coadministered in a single dosage form. All modes of administrations are contemplated, e.g., orally, rectally, parenterally, intranasally and topically.

A therapeutic composition containing the anti-convulsant and nontoxic NMDA receptor blocker or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation will ordinarily be formulated with

one or more pharmaceutically acceptable ingredients in accordance with known and established practice. Thus, the composition can be formulated as a liquid, powder, elixir, injectable solution, etc. Formulations for oral use can be provided as tablets or hard capsules wherein the pharmacologically active ingredients are mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients are mixed with an oleaginous medium, e.g., liquid paraffin or olive oil.

Aqueous suspensions can include pharmaceutically acceptable excipients such as suspending agents, e.g., sodium carboxymethyl cellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as naturally occurring phosphatide, e.g., lecithin, or condensation products of an alkylene oxide with fatty acids, e.g., polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, e.g., heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol, e.g., polyoxyethylene sorbitol monoleate or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, e.g., polyoxyethylene sorbitan monoleate. The aqueous suspensions can also contain one or more preservatives, e.g., ethyl-or-n-propyl-p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, saccharin or sodium or calcium cyclamate.

In addition to anticonvulsant and nontoxic NMDA receptor blocker or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation, the therapeutic composition herein can optionally contain at least one other pharmacologically active substance e.g., a non-narcotic analgesic such as acetaminophen or a non-steroidal anti-inflammatory drug (NSAID) such as aspirin, diclofenac, diflusal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, zomepirac, and the like.

WHAT IS CLAIMED IS:

1. A therapeutic composition comprising (a) a neuropathic pain-alleviating amount of at least one anticonvulsant and (b) an anticonvulsant-potentiating amount  
5 of at least one nontoxic antagonist for the NMDA receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation.
2. The therapeutic composition of Claim 1  
10 wherein anticonvulsant (a) is at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide,  
15 methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-  
20 hydroxytryptophan.
3. The therapeutic composition of Claim 1 wherein nontoxic NMDA receptor blocker (b) is at least one member selected from the group consisting of  
25 dextromethorphan, dextrothorphan, amantadine, memantine and pharmaceutically acceptable salt thereof.
4. The therapeutic composition of Claim 1 wherein (a) and (b) each is present in the same or different  
30 sustained release carrier.

5. The therapeutic composition of Claim 1 containing a therapeutically effective amount of at least one other pharmacologically active substance (c).

5 6. The therapeutic composition of Claim 1 containing a therapeutically effective amount of at least one other pharmacologically effective substance (c) selected from the group consisting of acetaminophen and nonsteroidal anti-inflammatory drug.

10 7. The therapeutic composition of claim 1 wherein anticonvulsant (a) is at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, 15 diphenylhydantoin, phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, 20 paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan and nontoxic NMDA receptor blocker (b) is dextromethorphan, or pharmaceutically acceptable salt thereof.

25 8. A method of alleviating neuropathic pain which comprises administering to a mammal exhibiting neuropathic pain (a) a neuropathic pain-alleviating amount of at least one anticonvulsant and (b) an anticonvulsant- 30 potentiating amount of at least one nontoxic antagonist for the NMDA receptor or nontoxic substance that blocks a major

intracellular consequence of NMDA receptor activation with (a) being administered prior to, with or following the administration of (b).

5                   9.    The method of Claim 8 wherein anticonvulsant  
    (a) is at least one member selected from the group  
    consisting of lamotrigine, gabapentin, valproic acid,  
    topiramate, famotodine, phenobarbital, diphenylhydantoin,  
    phenytoin, mephenytoin, ethotoin, mephobarbital, primidone,  
10    carbamazepine, ethosuximide, methsuximide, phensuximide,  
    trimethadione, benzodiazepine, phenacemide, acetazolamide,  
    progabide, clonazepam, divalproex sodium, magnesium sulfate  
    injection, metharbital, paramethadione, phenytoin sodium,  
    valproate sodium, clobazam, sulthiame, dilantin, diphenylan  
15    and L-5-hydroxytryptophan.

                  10.   The method of Claim 8 wherein nontoxic NMDA  
    receptor blocker (b) is at least one member selected from  
    the group consisting of dextromethorphan, dextrorphan,  
20    amantadine, memantine and pharmaceutically acceptable salt  
    thereof.

                  11.   The method of Claim 8 wherein (a) and (b) are  
    coadministered as a sustained release dosage form.  
25

                  12.   The method of Claim 8 wherein anticonvulsant  
    (a) is at least one member selected from the group  
    consisting of lamotrigine, gabapentin, valproic acid,  
    topiramate, famotodine, phenobarbital, diphenylhydantoin,  
30    phenytoin, mephenytoin, ethotoin, mephobarbital, primidone,  
    carbamazepine, ethosuximide, methsuximide, phensuximide,



trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan  
5 and L-5-hydroxytryptophan and nontoxic NMDA receptor blocker (b) is at least one member selected from the group consisting of dextromethorphan, dextrorphan, amantadine, memantine and pharmaceutically acceptable salt thereof and (a) and (b) are coadministered as a single dosage unit.

10

13. The method of claim 8 wherein anticonvulsant (a) is at least one member selected from the group consisting of lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin,  
15 phenytoin, mephenytoin, ethotoin, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium,  
20 valproate sodium, clobazam, sulthiame, dilantin, diphenylan and L-5-hydroxytryptophan and nontoxic NMDA receptor blocker (b) is dextromethorphan, or pharmaceutically acceptable salt thereof.

# INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/US 97/14680

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K45/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 87 01036 A (UNIV NEW YORK) 26 February 1987 see claims 10,13,17 see page 2, line 6-29 ---	1-3,810
A	WO 89 05642 A (FERKANY JOHN W ;PONTECORVO MICHAEL J (US)) 29 June 1989 see abstract ---	1-13
A	US 5 234 929 A (CHELEN WILLIAM) 10 August 1993 see abstract ---	1-13
A	WO 89 05641 A (PONTECORVO MICHAEL J ;FERKANY JOHN W (US)) 29 June 1989 see claims ---	1-13
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "S" document member of the same patent family

Date of the actual completion of the international search

4 December 1997

Date of mailing of the international search report

15.01.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/14680

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 459 695 A (MCNEIL PPC INC) 4 December 1991 see abstract see claims 1,2 ---	4,11
A	EP 0 615 749 A (UNIV VIRGINIA COMMONWEALTH) 21 September 1994 see abstract -----	1-13

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 97/14680

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8701036 A	26-02-87	US 4694010 A AU 579028 B AU 6283786 A DK 178687 A EP 0233932 A JP 63500598 T US 4898860 A	15-09-87 10-11-88 10-03-87 08-04-87 02-09-87 03-03-88 06-02-90
WO 8905642 A	29-06-89	AU 2929489 A EP 0346445 A	19-07-89 20-12-89
US 5234929 A	10-08-93	NONE	
WO 8905641 A	29-06-89	US 4906638 A AU 2927989 A EP 0371085 A JP 2502545 T	06-03-90 19-07-89 06-06-90 16-08-90
EP 0459695 A	04-12-91	IN 172428 A US 5075114 A AU 639334 B AU 7723491 A CA 2042289 A GR 91100204 A JP 6316536 A ES 2073677 T IE 67062 B US 5460825 A	24-07-93 24-12-91 22-07-93 28-11-91 24-11-91 30-07-92 15-11-94 16-08-95 21-02-96 24-10-95
EP 0615749 A	21-09-94	US 5352683 A CA 2115792 A JP 7002671 A US 5502058 A	04-10-94 06-09-94 06-01-95 26-03-96



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 45/06</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/07447</b> <b>(43) International Publication Date:</b> 26 February 1998 (26.02.98)
<b>(21) International Application Number:</b> PCT/US97/14680 <b>(22) International Filing Date:</b> 21 August 1997 (21.08.97) <b>(30) Priority Data:</b> 60/024,508 23 August 1996 (23.08.96) US <b>(71) Applicant (for all designated States except US):</b> ALGOS PHARMACEUTICAL CORPORATION [US/US]; Colling- wood Plaza, 4900 Route 33, Neptune, NJ 07753 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> CARUSO, Frank, S. [US/US]; 2 Bowling Green, Colts Neck, NJ 07722 (US). MINN, Fredrick, L. [US/US]; 601 Midway Lane, Blue Bell, PA 19422 (US). LYLE, John, W. [US/US]; 28 Inlet Terrace, Belmar, NJ 07719 (US). <b>(74) Agents:</b> DILWORTH, Peter, G. et al.; Dilworth & Barrese, 333 Earle Ovington Boulevard, Uniondale, NY 11553 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>With amended claims.</i>  <b>Date of publication of the amended claims:</b> 26 March 1998 (26.03.98)
<b>(54) Title:</b> ANTICONVULSANT CONTAINING COMPOSITION FOR TREATING NEUROPATHIC PAIN		
<b>(57) Abstract</b>  Composition for alleviating neuropathic pain which a neuropathic pain-alleviating amount of an anticonvulsant is combined with an anticonvulsant-potentiating amount of a nontoxic antagonist, or blocker, for the N-methyl-D-aspartate (NMDA) receptor or nontoxic substance that blocks a major intracellular consequence of NMDA receptor activation.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## AMENDED CLAIMS

[received by the International Bureau on 10 February 1998 (10.02.98);  
new claims 14-19 added; remaining claims unchanged (2 pages)]

- trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan  
5 and L-5-hydroxytryptophan and nontoxic NMDA receptor blocker  
(b) is at least one member selected from the group  
consisting of dextromethorphan, dextrothorphan, amantadine, memantine and pharmaceutically acceptable salt thereof and  
(a) and (b) are coadministered as a single dosage unit.
- 10 13. The method of claim 8 wherein anticonvulsant  
(a) is at least one member selected from the group  
consisting of lamotrigine, gabapentin, valproic acid, topiramate, famotidine, phenobarbital, diphenylhydantoin, phenytoin, mephentyoin, ethotoin, mephobarbital, primidone,  
15 carbamazepine, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacemide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan  
20 and L-5-hydroxytryptophan and nontoxic NMDA receptor blocker  
(b) is dextromethorphan, or pharmaceutically acceptable salt thereof.
14. The therapeutic composition of Claim 1 further comprising (c) an analgesic.
- 25 15. The therapeutic composition of Claim 14 wherein the analgesic is a non-narcotic analgesic.

16. The therapeutic composition of Claim 15 wherein the non-narcotic analgesic is at least one member selected from the group consisting of acetaminophen, aspirin, diclofenac, diflusal, etodolac, fenbufen, 5 fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin and zomepirac.

17. The method of Claim 8 further 10 comprising (c) an analgesic.

18. The method of Claim 17 wherein the analgesic is a non-narcotic analgesic.

19. The method of Claim 18 wherein the non-narcotic analgesic is at least one member selected from the 15 group consisting of acetaminophen, aspirin, diclofenac, diflusal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, 20 tolmetin and zomepirac.